For ADC, DAC, bispecific, and degrader programs: quantify antigen density, target engagement, and immune-mediated cytotoxicity (as confirmed for each program) directly in primary blood cancer-derived cells.
Designed for ADCs, bispecifics / T-cell engagers, and targeted degraders — the modalities whose success depends on target expression and engagement in real patient cells.
* Not intended for cell- or gene-therapy products as the test article
Antigen-density quantification
By flow cytometry, gated on malignant vs. non-malignant populations
Target-engagement readouts
Receptor occupancy and target-protein degradation
Immune-mediated cytotoxicity (confirmed per program)
Killing-efficacy assays for bispecific and T-cell-engager candidates
Population resolution
Response and engagement resolved in the cell population that matters, not in the bulk well
For target-dependent modalities, expression, engagement, and killing in real patient cells are the gating questions — answered before the clinic, on the xCellSense® platform.
Key Deliverables
A scientist — not a sales desk — will scope a tailored study and return a design and timeline.
